276 related articles for article (PubMed ID: 22721387)
1. The role of mesothelin in tumor progression and targeted therapy.
Tang Z; Qian M; Ho M
Anticancer Agents Med Chem; 2013 Feb; 13(2):276-80. PubMed ID: 22721387
[TBL] [Abstract][Full Text] [Related]
2. Discovery of mesothelin and exploiting it as a target for immunotherapy.
Pastan I; Hassan R
Cancer Res; 2014 Jun; 74(11):2907-12. PubMed ID: 24824231
[TBL] [Abstract][Full Text] [Related]
3. Mesothelin-targeted agents in clinical trials and in preclinical development.
Kelly RJ; Sharon E; Pastan I; Hassan R
Mol Cancer Ther; 2012 Mar; 11(3):517-25. PubMed ID: 22351743
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin targeted cancer immunotherapy.
Hassan R; Ho M
Eur J Cancer; 2008 Jan; 44(1):46-53. PubMed ID: 17945478
[TBL] [Abstract][Full Text] [Related]
5. Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin.
Ho M
BioDrugs; 2011 Oct; 25(5):275-84. PubMed ID: 21942912
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Hassan R; Ebel W; Routhier EL; Patel R; Kline JB; Zhang J; Chao Q; Jacob S; Turchin H; Gibbs L; Phillips MD; Mudali S; Iacobuzio-Donahue C; Jaffee EM; Moreno M; Pastan I; Sass PM; Nicolaides NC; Grasso L
Cancer Immun; 2007 Dec; 7():20. PubMed ID: 18088084
[TBL] [Abstract][Full Text] [Related]
7. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Matsuzawa F; Kamachi H; Mizukami T; Einama T; Kawamata F; Fujii Y; Fukai M; Kobayashi N; Hatanaka Y; Taketomi A
BMC Cancer; 2021 Feb; 21(1):200. PubMed ID: 33637083
[TBL] [Abstract][Full Text] [Related]
8. A novel high-affinity human monoclonal antibody to mesothelin.
Ho M; Feng M; Fisher RJ; Rader C; Pastan I
Int J Cancer; 2011 May; 128(9):2020-30. PubMed ID: 20635390
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.
Hassan R; Cohen SJ; Phillips M; Pastan I; Sharon E; Kelly RJ; Schweizer C; Weil S; Laheru D
Clin Cancer Res; 2010 Dec; 16(24):6132-8. PubMed ID: 21037025
[TBL] [Abstract][Full Text] [Related]
10. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
11. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
Hassan R; Schweizer C; Lu KF; Schuler B; Remaley AT; Weil SC; Pastan I
Lung Cancer; 2010 Jun; 68(3):455-9. PubMed ID: 19744744
[TBL] [Abstract][Full Text] [Related]
13. CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.
Nicolaides NC; Schweizer C; Somers EB; Wang W; Fernando S; Ross EN; Grasso L; Hassan R; Kline JB
Cancer Biol Ther; 2018 Jul; 19(7):622-630. PubMed ID: 29652548
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.
Zhang Y; Chertov O; Zhang J; Hassan R; Pastan I
Cancer Res; 2011 Sep; 71(17):5915-22. PubMed ID: 21775520
[TBL] [Abstract][Full Text] [Related]
15. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.
Zhang YF; Phung Y; Gao W; Kawa S; Hassan R; Pastan I; Ho M
Sci Rep; 2015 May; 5():9928. PubMed ID: 25996440
[TBL] [Abstract][Full Text] [Related]
16. Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.
Awuah P; Bera TK; Folivi M; Chertov O; Pastan I
Mol Cancer Ther; 2016 Jul; 15(7):1648-55. PubMed ID: 27196771
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
18. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.
Tang Z; Feng M; Gao W; Phung Y; Chen W; Chaudhary A; St Croix B; Qian M; Dimitrov DS; Ho M
Mol Cancer Ther; 2013 Apr; 12(4):416-26. PubMed ID: 23371858
[TBL] [Abstract][Full Text] [Related]
19. Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.
Sirois AR; Deny DA; Baierl SR; George KS; Moore SJ
PLoS One; 2018; 13(5):e0197029. PubMed ID: 29738555
[TBL] [Abstract][Full Text] [Related]
20. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.
Feng Y; Xiao X; Zhu Z; Streaker E; Ho M; Pastan I; Dimitrov DS
Mol Cancer Ther; 2009 May; 8(5):1113-8. PubMed ID: 19417159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
